306936-38-9 Usage
Uses
Used in Pharmaceutical Industry:
2-Methyl-5-(piperidinosulfonyl)-3-furoic acid is used as an anti-inflammatory agent for its ability to reduce the production of pro-inflammatory cytokines. This property makes it a candidate for the treatment of inflammatory conditions where such cytokines play a significant role in disease progression.
Used in Autoimmune Disease Treatment:
In the field of immunology, MPAF is utilized as a therapeutic agent for autoimmune diseases. Its capacity to modulate the activity of immune cells and disrupt inflammatory signaling pathways offers potential benefits in managing the symptoms and progression of various autoimmune disorders.
Used in Research and Development:
MPAF is also used as a research tool in the scientific community to study the role of protein tyrosine phosphatases in inflammatory and immune responses. This helps in understanding the underlying mechanisms of disease and identifying new targets for therapeutic intervention.
The ongoing exploration of MPAF's potential applications underscores its importance in advancing medical and pharmacological knowledge, with the aim of developing more effective treatments for a range of conditions characterized by inflammation and immune dysregulation.
Check Digit Verification of cas no
The CAS Registry Mumber 306936-38-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,6,9,3 and 6 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 306936-38:
(8*3)+(7*0)+(6*6)+(5*9)+(4*3)+(3*6)+(2*3)+(1*8)=149
149 % 10 = 9
So 306936-38-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H15NO5S/c1-8-9(11(13)14)7-10(17-8)18(15,16)12-5-3-2-4-6-12/h7H,2-6H2,1H3,(H,13,14)
306936-38-9Relevant academic research and scientific papers
Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors
Goodman, Krista B.,Bury, Michael J.,Cheung, Mui,Cichy-Knight, Maria A.,Dowdell, Sarah E.,Dunn, Allison K.,Lee, Dennis,Lieby, Jeffrey A.,Moore, Michael L.,Scherzer, Daryl A.,Sha, Deyou,Suarez, Dominic P.,Murphy, Dennis J.,Harpel, Mark R.,Manas, Eric S.,McNulty, Dean E.,Annan, Roland S.,Matico, Rosalie E.,Schwartz, Benjamin K.,Trill, John J.,Sweitzer, Thomas D.,Wang, Da-yuan,Keller, Paul M.,Krawiec, John A.,Jaye, Michael C.
supporting information; scheme or table, p. 27 - 30 (2009/05/07)
Endothelial lipase (EL) activity has been implicated in HDL catabolism, vascular inflammation, and atherogenesis, and inhibitors are therefore expected to be useful for the treatment of cardiovascular disease. Sulfonylfuran urea 1 was identified in a high-throughput screening campaign as a potent and non-selective EL inhibitor. A lead optimization effort was undertaken to improve potency and selectivity, and modifications leading to improved LPL selectivity were identified. Radiolabeling studies were undertaken to establish the mechanism of action for these inhibitors, which were ultimately demonstrated to be irreversible inhibitors.
